Last reviewed · How we verify
DU-176b tablets
DU-176b tablets are a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.
DU-176b tablets are a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain. Used for Major depressive disorder, Generalized anxiety disorder.
At a glance
| Generic name | DU-176b tablets |
|---|---|
| Sponsor | Daiichi Sankyo Co., Ltd. |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 2 |
Mechanism of action
By increasing serotonin levels, DU-176b tablets help to improve mood, reduce anxiety, and alleviate symptoms of depression. SSRIs like DU-176b tablets are commonly used to treat major depressive disorder, generalized anxiety disorder, and other conditions.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Insomnia
Key clinical trials
- Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease (PHASE3)
- Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) (PHASE3)
- Cancer Venous Thromboembolism (VTE) (PHASE3)
- A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (PHASE3)
- Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (PHASE3)
- Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery (PHASE3)
- A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (PHASE3)
- Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DU-176b tablets CI brief — competitive landscape report
- DU-176b tablets updates RSS · CI watch RSS
- Daiichi Sankyo Co., Ltd. portfolio CI